Sage Therapeutics Inc
SAGE
Get informed when a big investor buys or sells
+ FollowMarket Cap$544.94M
Close$
$-8.39
196.7% downside
Current Fair Value
196.7% downsideOvervalued by 196.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $544.94 Million |
|---|---|
| Enterprise Value | $489.57 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.59 |
| Beta | 0.3 |
| Outstanding Shares | 62,610,598 |
Return
| Return on Equity | -81.68% |
|---|---|
| Return on Assets | -71.22% |
| Return on Invested Capital | -80.12% |
Valuation & Multiples
| P/E Ratio | -2.62 |
|---|---|
| PEG | 5.06 |
| Price to Sales | 8.68 |
| Price to Book Ratio | 1.74 |
| Enterprise Value to Revenue | 6.95 |
| Enterprise Value to EBIT | -1.62 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5850▼ 112.80% |
|---|---|
| Total Calls | 752,500▲ 313.69% |
| Total Puts | 440,200▲ 41.27% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 78.06%▼ 5.60% |
|---|---|
| Total Invested | $445.74M▲ 8.32% |
| Investors Holding | 204▼ 1.00% |
ESG Score
No data
About Sage Therapeutics Inc
CEO: Jeffrey Jonas Relevant Senate Committees
Finance
Controls Medicare and Medicaid reimbursement policy; Sage's commercial success depends heavily on these pricing and access decisions.
Health, Education, Labor, and Pensions
Direct oversight of the FDA makes this committee essential; its members may have non-public insights into drug approval processes and safety standards.
Special Committee on Aging
Hearings on drug pricing and neurological conditions like Alzheimer's and tremors create high headline risk and regulatory pressure for Sage's pipeline.